A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B

Status:
Recruiting

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-221 in healthy male subjects.

Phase 1

Addpharma Inc.